Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923083 | 0.85 | KLKB1 (0.34) | HTR2CXPO1RXRAGRIN1GRIN2B | |
| SCHEMBL2921514 | 0.85 | HTR2C (0.32) | GABRG2GABRB3GABRA5CYP17A1HTR2C | |
| SCHEMBL2940359 | 0.84 | XPO1 (0.35) | GABRG2GABRB3GABRA5HTR2CXPO1 | |
| SCHEMBL27952843 | 0.82 | CYP17A1 (0.31) | CYP17A1XPO1HCRTR1 | |
| SCHEMBL2916881 | 0.81 | TLR9 (0.35) | XPO1 | |
| SCHEMBL2916380 | 0.81 | XPO1 (0.34) | GABRG2GABRB3GABRA5XPO1ENPP2 | |
| SCHEMBL27941586 | 0.81 | XPO1 (0.34) | GABRG2GABRB3GABRA5XPO1 | |
| SCHEMBL2913112 | 0.79 | CYP17A1 (0.34) | CYP17A1 | |
| SCHEMBL27952869 | 0.79 | XPO1 (0.32) | XPO1ENPP2 | |
| SCHEMBL2913915 | 0.78 | POLB (0.38) | GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648207-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8440838-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | CYP1A1, CYP2S1, NAT1 | GABRG2 1727/4885GABRB3 2893/4885GABRA5 2196/4885 |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | CYP1B1, CYP1A1, AOC3 | GABRG2 975/4885GABRB3 526/4885GABRA5 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.